Milestone Pharmaceuticals enrolls first European patient in AFib trial
Tweet Send to a Friend
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) announced that the first European participant has been enrolled in its ReVeRA-301 Phase 3 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




